Atossa Therapeutics (ATOS) Total Non-Current Liabilities (2013 - 2023)
Atossa Therapeutics (ATOS) posted quarterly Total Non-Current Liabilities of $3.4 million for Q3 2023, down 0.98% quarter-over-quarter from $3.5 million in Q2 2023.
Atossa Therapeutics (ATOS) Total Non-Current Liabilities (2013 - 2023) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Total Non-Current Liabilities for 4 consecutive years, with $3.4 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $3.4 million; the TTM figure through Sep 2023 stood at $3.4 million (changed N/A YoY), while the FY2022 annual figure was $5.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $3.4 million in Q3 2023 per ATOS's latest filing, from $3.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.6 million in Q4 2022 and bottomed at $3.4 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 9.32 Bn |
| 10 | Atossa Therapeutics | 22.76 Mn | 22.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Dec 31, 2022 | 5.57 Mn |
| Dec 31, 2014 | 2.19 Mn |
| Dec 31, 2013 | 1.40 Mn |